



FLUCLOXACILLIN

SYNONYMS	Floxacillin sodium
BRAND NAME	FLUBICLOX, FLUCIL, FLUCLOXACILLIN KABI
DRUG CLASS	Penicillin antibiotic
AVAILABILITY	Vial contains 500 mg, 1 g or 2 g of flucloxacillin sodium. ¹ 1 g of flucloxacillin sodium contains 2.2 mmol of sodium. ^{1,2} 2 g of flucloxacillin sodium contains 4.52 mmol of sodium. ¹
WARNING	This is a penicillin. If the patient has a history of hypersensitivity to penicillins confirm antibiotic choice with the treating team. Pain and phlebitis are common and can be severe. ³ Use a central line (or PICC) for prolonged treatment and for continuous infusions.
pH	Approximately 5–7 when reconstituted ⁴
PREPARATION	<p>For IM use: reconstitute the 500 mg vial with 2 mL of water for injections and the 1 g vial with 2.5 mL of water for injections. May be reconstituted with lidocaine 1%.¹ Do not inject solutions that have been reconstituted with lidocaine intravenously.</p> <p>For IV use: reconstitute the 500 mg vial with 10 mL of water for injections, the 1 g vial with 15–20 mL of water for injections (the current Flubiclox 1 g vial will not accommodate more than 10 mL), or the 2 g vial with 40 mL of water for injections.¹ The reconstituted solution is clear.⁴</p> <p>Powder volumes and part-dosing: Flucil: 500 mg – 0.4 mL, 1 g – 0.7 mL. Reconstitute the 500 mg vial with 4.6 mL or the 1 g vial with 9.3 mL of water for injections to make a concentration of 100 mg/mL.¹ Flubiclox: 1 g – 0.8 mL, 2 g – 1.5 mL.^{1,5} Reconstitute the 1 g vial with 9.2 mL of water for injections to make a concentration of 100 mg/mL. Kabi: 1 g – 1 mL. Reconstitute the 1 g vial with 19 mL of water for injections to make a concentration of 50 mg/mL.⁶</p>
STABILITY	<p>Vial: store below 25 °C. Protect from light.¹ Reconstituted solution: use immediately.¹ Infusion solution: stable for 24 hours at 2 to 8 °C.¹ Concentrations of 5 mg/mL and 60 mg/mL in sodium chloride 0.9% prepared in a sterile production unit are stable for 3 days at 2 to 8 °C.⁷</p> <p>Buffered solutions for CoPAT use: Concentrations of 5 mg and 60 mg/mL in citrate-buffered sodium chloride 0.9% are stable for 24 hours at 37 °C. Use 4.7 mL of sodium citrate 4% to reconstitute the 1 g vial.⁷ Concentrations of 10 mg/mL and 50 mg/mL in citrate-buffered saline are stable for 24 hours at 32 °C.⁸ Concentrations of 50 mg/mL and 120 mg/mL in phosphate-buffered sodium chloride 0.9% are stable for 24 hours at 37 °C.⁹ Buffered solutions prepared in a sterile production unit are stable for 14 days at 2 to 8 °C.^{8,9}</p> <p>Unbuffered solutions for CoPAT use: Concentrations of 50 mg/mL in sodium chloride 0.9% are stable for 24 hours at 31 °C.⁸ Stable for less than 12 hours at 37 °C.^{9,10} For 24 hour continuous infusions use a buffered solution or consider splitting the dose and providing as two 12 hour infusions; store the second bag at 2 to 8 °C until ready to use.¹¹</p> <p><i>continued over the page</i></p>

ADMINISTRATION**IM injection** Suitable for adults and children.¹ The injection is painful.**SUBCUT injection** Not recommended**IV injection** Inject the dose slowly over 3 to 4 minutes.¹ A dose of 2 g can be injected over 6 to 8 minutes, however infusion is preferred as phlebitis is common.**IV infusion** Preferred route for large doses e.g. 2 g. Dilute the dose in a suitable volume of a compatible fluid and infuse over 30 to 60 minutes.
The total daily dose (8 to 12 g) may be given as a 24 hour continuous infusion in the community setting.¹¹ See STABILITY**IV use for infants and children** Dilute to a convenient volume and infuse over 30 to 60 minutes.¹²
May be given by IV injection over 3 to 4 minutes, however pain and phlebitis are common and can be severe.^{1,12}**Other** Suitable for intrapleural and intra-articular use.¹**COMPATIBILITY****Fluids** Sodium chloride 0.9%^{1,2}, glucose 5%^{1,2}, glucose in sodium chloride solutions^{1,2}, Hartmann's², Plasma-Lyte 148 via Y-site¹³**Y-site** No information**INCOMPATIBILITY****Fluids** Blood products¹, protein-containing fluids¹**Drugs** Aminoglycosides: amikacin, gentamicin, tobramycin¹, amiodarone², atropine², buprenorphine², calcium gluconate², ciprofloxacin², dobutamine², erythromycin², lorazepam¹⁴, metoclopramide², midazolam¹⁴, morphine sulfate², pethidine², promethazine², vancomycin¹⁴, verapamil²**REFERENCES**

1. Product information. Available from www.tga.gov.au. Accessed 16/05/2025.
2. ASHP Injectable drug information 2021. Bethesda, MD: American Society of Health-System Pharmacists; 2021.
3. Svedhem A, Alestig K, Jertborn M. Phlebitis induced by parenteral treatment with flucloxacillin and cloxacillin: a double-blind study. *Antimicrob Agents Chemother* 1980; 18: 349-52.
4. Medical information. Flucil flucloxacillin injection. [email]. St Leonards, NSW: Aspen Pharmacare Pty Ltd; 14/09/2022.
5. Medical affairs. Flucloxacillin [email]. Richmond, Vic: Juno Pharmaceuticals; 10/10/2024.
6. Medical affairs. Flucloxacillin [email]. Mount Kuring-gai, NSW: Fresenius Kabi Australia; 24/10/2024.
7. Smith EK, McWhinney BC. Stability of buffered benzylpenicillin and flucloxacillin for a paediatric outpatient parenteral antibiotic therapy service. *J Pharm Pract Res* 2021; 51: 231-7.
8. Allwood MC, Stonkute D, Wallace A, Wilkinson A-S, Hills T, Jamieson C. Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INFusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements. *Eur J Hosp Pharm* 2018; 0: 1-5.
9. To T-P, Ching MS, Ellis AG, Williams L, Garrett MK. Stability of intravenous flucloxacillin solutions used for hospital-in-the-home. *J Pharm Pract Res* 2010; 40: 101-5.
10. Carroll JA. Stability of flucloxacillin in elastomeric infusion devices. *J Pharm Pract Res* 2005; 35: 90-2.
11. Community-based parenteral antimicrobial therapy [May 2022]. In: *Therapeutic Guidelines* [internet]. Melbourne: Therapeutic Guidelines Limited; August 2022.
12. Paediatric Formulary Committee. BNF for children. London: BMJ group and Pharmaceutical Press; 2022-2023.
13. Medical information. Plasma-Lyte 148 compatibility summary. Toongabbie, NSW: Baxter; March 2022.
14. Floxacillin sodium. In: *IV Index* [internet]. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Ann Arbor, MI: Merative. Accessed 06/01/2023.

VERSION

9.1